Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis
Authors' conclusion
Both small-molecule drugs and biologic therapy are valuable options for PsO treatment, and their use can be tailored toward specific individuals or healthcare systems.
Study context
- Population
- Moderate-to-severe psoriasis (PsO) after failure of conventional therapy
- Comparison
- Oral targeted small-molecule drugs vs biologic therapy as first-line systemic therapy after failure of conventional therapy
Methodological detailsnarrative review of a GRAPPA 2023 annual meeting debate
- Narrative review of a GRAPPA 2023 annual meeting debate
Main finding
As reported in the abstract
- Arguments for small-molecule drugs: good efficacy and safety, patient preference, cost savings, global health equity, environmental stewardship
- Arguments for biologics: superior efficacy, excellent safety, long-term data, pediatric regulatory approvals, potential benefit for comorbidities
- Significant pros and cons of each approach recognised by the end of the debate
Original publication
GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis. J Rheumatol. Published 15 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →